Abstract:The development of a safe and effective COVID-19 vaccine is of paramount importance to terminate the current pandemic. An adjuvant is crucial for improving the efficacy of the subunit COVID19 vaccine. α-Galactosylceramide (αGC) is a classical iNKT cell agonist which causes the rapid production of Th1- and Th2-associated cytokines; we, therefore, expect that the Th1- or Th2-skewing analogues of αGC can better enhance the immunogenicity of the receptor-binding domain in the spike protein of SARS-CoV-2 fused with the Fc region of human IgG (RBD-Fc). Herein, we developed a universal synthetic route to the Th1-biasing (α-C-GC) and Th2-biasing (OCH and C20:2) analogues. Immunization of mice demonstrated that αGC-adjuvanted RBD-Fc elicited a more potent humoral response than that observed with Alum and enabled the sparing of antigens. Remarkably, at a low dose of the RBD-Fc protein (2 μg), the Th2-biasing agonist C20:2 induced a significantly higher titer of the neutralizing antibody than that of Alum.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00881?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00881</a>.Compound characterization spectra (HPLC-ELSD, <sup>1</sup>H NMR, and <sup>13</sup>C NMR), vaccine liposomal formulations, information of RBD-Fc and RBD-His, and biological assays (IgM, IgG subtype response induced by a different dose of RBD-Fc) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00881/suppl_file/jm1c00881_si_001.pdf">PDF</a>)Molecular formula strings of the compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00881/suppl_file/jm1c00881_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist